Literature DB >> 2681310

Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view.

M Schetz1, P M Lauwers, P Ferdinande.   

Abstract

Acute renal failure in critically ill patients is seldom an isolated problem but is more usually associated with multiple organ failure. When choosing an extracorporeal kidney replacement therapy, these other failing organs must be taken into account. Therefore the choice of an artificial kidney in patients requiring intensive care depends on both the efficacy of the technique and its possible adverse effects on cerebral, pulmonary and cardiovascular function. The most important pathogenic factors in the development of dysequilibrium syndromes, arterial hypoxemia and hypotension are treatment timing, diffusive solute transfer, bio-incompatible membranes and some specific dialysate components (buffer, electrolyte concentrations). It is important to understand the mechanisms by which these factors exert their adverse effects. Application of these pathophysiological mechanisms to the cardiopulmonary and neurologic status of the individual patient permits the prediction of their clinical outcome. This approach will lead to individualised treatment selection, thereby avoiding deleterious side-effects without loss of efficacy.

Entities:  

Mesh:

Year:  1989        PMID: 2681310     DOI: 10.1007/bf00261492

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  64 in total

1.  A vasodilator action of acetates.

Authors:  W Bauer; D W Richards
Journal:  J Physiol       Date:  1928-12-20       Impact factor: 5.182

2.  Continuous arteriovenous hemofiltration with AN69S membrane; procedures and experience.

Authors:  C Ronco; A Brendolan; L Bragantini; S Chiaramonte; M Feriani; A Fabris; R Dell'Aquila; G La Greca; M Milan
Journal:  Kidney Int Suppl       Date:  1988-03       Impact factor: 10.545

3.  Importance of the plasma refilling rate in the genesis of hypovolaemic hypotension during regular dialysis and controlled sequential ultrafiltration-haemodialysis.

Authors:  J J Rouby; J Rottembourg; J P Durande; J Y Basset; M Legrain
Journal:  Proc Eur Dial Transplant Assoc       Date:  1978

4.  Oxygen consumption during maintenance hemodialysis.

Authors:  A Blumberg; G Keller
Journal:  Nephron       Date:  1979       Impact factor: 2.847

Review 5.  Acetate metabolism during hemodialysis: metabolic considerations.

Authors:  P Vinay; M Cardoso; A Tejedor; M Prud'homme; M Levelillee; B Vinet; M Courteau; A Gougoux; M Rengel; L Lapierre
Journal:  Am J Nephrol       Date:  1987       Impact factor: 3.754

6.  Hypoxemia during hemodialysis.

Authors:  G C Carlon; P B Campfield; P L Goldiner; A D Turnbull
Journal:  Crit Care Med       Date:  1979-11       Impact factor: 7.598

7.  Continuous arteriovenous hemofiltration. A report of six months' experience.

Authors:  A A Kaplan; R E Longnecker; V W Folkert
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

Review 8.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

9.  Acetate versus bicarbonate hemodialysis in critically ill patients.

Authors:  K M Leunissen; S J Hoorntje; H A Fiers; W T Dekkers; A W Mulder
Journal:  Nephron       Date:  1986       Impact factor: 2.847

10.  Influence of ultrafiltration on plasma renin activity and adrenergic system.

Authors:  P Zucchelli; L Catizone; E D Esposti; M Fusaroli; A Ligabue; A Zuccalà
Journal:  Nephron       Date:  1978       Impact factor: 2.847

View more
  16 in total

1.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Progressive hypercalcemia during continuous arterio-venous ultrafiltration (SCUF).

Authors:  H E van der Wiel; H J Voerman; L G Thijs
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

3.  The haemodynamic effects of intermittent haemofiltration in critically ill patients.

Authors:  S J MacKenzie; G R Nimmo; I R Armstrong; I S Grant
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  The consequences of continuous haemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock model.

Authors:  B Stein; E Pfenninger; A Grünert; J E Schmitz; A Deller; F Kocher
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

5.  Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock.

Authors:  B Stein; E Pfenninger; A Grünert; J E Schmitz; M Hudde
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 6.  Pharmacokinetics of continuous renal replacement therapy.

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

7.  Peritoneal dialysis for acute renal failure.

Authors:  R Daelemans; L F Lauwers; R L Lins
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Intermittent hemodialysis in critically ill patients with multiple organ dysfunction syndrome is associated with intestinal intramucosal acidosis.

Authors:  G Van der Schueren; M Diltoer; M Laureys; L Huyghens
Journal:  Intensive Care Med       Date:  1996-08       Impact factor: 17.440

9.  Continuous veno-venous haemofiltration following cardio-pulmonary bypass. Indications and outcome in 35 patients.

Authors:  S V Baudouin; J Wiggins; B F Keogh; C J Morgan; T W Evans
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study.

Authors:  R Bellomo; H Teede; N Boyce
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.